EGFR and prostate adenocarcinoma: Two study participants had partial response, one with neuroendocrine prostate cancer (NEPC) transformed from high-risk prostate adenocarcinoma and one with SCLC transformed from epidermal growth factor receptor (EGFR)-mutated NSCLC.